🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Georgia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Georgia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9115 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Sep 2026, 03:16 UTC
9115
Studies in scope
industry-sponsored, all four open statuses
4955
Recruiting now
open to new participants
2206
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4396 Illinois 2477 Georgia 2346 Arizona 2230
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca104 Eli Lilly and Company87 Merck Sharp & Dohme LLC70 Janssen Research & Development, LLC67 AbbVie66
State
California5299 Florida4396 Illinois2477 Georgia2346 Arizona2230
All 51 states
Target enrolment
to

Trials with a site in Georgia

2346 of 9115 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07184996Ulcerative Colitis
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-08
Recruiting
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT07100106Breast Cancer
Genentech, Inc.
Phase 1/2
285
Arizona, California, Florida, Georgia, Illinois, Maine, Maryland, Massachusetts
2025-10-07
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Pfizer
Phase 2/3
982
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Hawaii
2025-10-03
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
Janssen Research & Development, LLC
Phase 2/3
1,092
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-03
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S
Phase 3
1,280
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois
2025-10-02
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
NCT06745908NSCLC Stage IV
ImmunityBio, Inc.
Phase 3
507
Arkansas, California, Florida, Georgia, Missouri, North Carolina, Ohio, South Carolina
2025-10-01
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
882
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-01
Recruiting
Study of COYA 302 for the Treatment of ALS
NCT07161999Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics
Phase 2/3
120
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-10-01
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-01
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, Pennsylvania
2025-09-30
Recruiting
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07116616Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
Phase 1/2
190
Alabama, California, Georgia, Massachusetts, New York, North Carolina, Pennsylvania, Tennessee
2025-09-30
Active, closed
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
NCT07220460Bipolar I or II Disorder
AbbVie
Phase 2
84
Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland
2025-09-30
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-09-30
Recruiting
IVUS CHIP UPP Registry
NCT06625801Coronary Artery Disease, Coronary Artery Disease Risk High, Complex Coronary Artery Disease
ECRI bv
Observational
1,010
Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan, Minnesota
2025-09-30
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Pfizer
Phase 3
680
Alabama, Alaska, Arkansas, California, Colorado, Delaware, Florida, Georgia
2025-09-29
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-09-28
Recruiting
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
NCT07129993Urothelial Cancer, Bladder Cancer
Daiichi Sankyo
Phase 2/3
630
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-09-26
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
Sanofi
Phase 3
124
California, Florida, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio
2025-09-26
Active, closed
SPHERE Per-AF Post-Approval Study
NCT06858306Persistent Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
200
Alabama, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Pennsylvania
2025-09-25
Active, closed
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
NCT07159763Influenza
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-09-25
Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423Chronic Obstructive Pulmonary Disease
Sanofi
Phase 4
218
Alabama, Florida, Georgia, Kansas, Maryland, Massachusetts, North Carolina, Pennsylvania
2025-09-22
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
Bristol-Myers Squibb
Phase 3
3,040
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-09-22
Recruiting
GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections
NCT06827990Aortic Dissection
W.L.Gore & Associates
Not applicable
112
Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-09-22
Active, closed
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
NCT07221578Social Anxiety Disorder (SAD)
Vanda Pharmaceuticals
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri
2025-09-22
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Alnylam Pharmaceuticals
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-09-22
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc.
Phase 1
40
California, Colorado, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas
2025-09-22
Recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578Alzheimers Disease
Hoffmann-La Roche
Phase 3
800
Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Louisiana
2025-09-17
Recruiting
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
NCT07023835Amyotrophic Lateral Sclerosis (ALS)
Zydus Therapeutics Inc.
Phase 2
240
California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Nebraska, North Carolina
2025-09-17
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-09-17
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
AstraZeneca
Observational
64
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, Missouri
2025-09-17
Recruiting
Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects
NCT07228026Asthma
Biometry Inc
Observational
160
California, Florida, Georgia, Maine, Maryland, Nebraska, North Carolina, Ohio
2025-09-17
Recruiting
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
NCT07037758Extensive Stage Small Cell Lung Cancer
Amgen
Phase 1
380
Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Missouri, New York
2025-09-16
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana
2025-09-16
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Kansas, Massachusetts
2025-09-15
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
Scholar Rock, Inc.
Phase 2
52
Arizona, California, Colorado, Georgia, Iowa, Michigan, Pennsylvania, Tennessee
2025-09-15
Recruiting
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
NCT07094087Complex Cardiovascular Surgery With Cardiopulmonary Bypass
CSL Behring
Phase 3
200
California, Georgia, Illinois, Kansas, Maryland, New Jersey, New York, Ohio
2025-09-15
Recruiting
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
NCT07090161Hypertension, Uncontrolled Hypertension
Vanda Pharmaceuticals
Phase 2
240
Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky, Missouri
2025-09-15
By invitation
5-Year Postoperative Outcomes of Patients Who Completed the CREST Study
NCT07480343Open-angle Glaucoma (OAG)
Iantrek, Inc.
Observational
250
California, Florida, Georgia, Maryland, Nevada, Pennsylvania, Tennessee, Utah
2025-09-15
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-09-13
Recruiting
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
NCT07013201Palmoplantar Pustulosis
LEO Pharma
Phase 2
135
California, Georgia, Michigan, New York, Ohio, Oregon, Pennsylvania
2025-09-11
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
Bristol-Myers Squibb
Phase 2/3
600
Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois, Louisiana
2025-09-11
Recruiting
AMEND TS Early Feasibility Study
NCT06951672Symptomatic Functional MR 3 or Greater
Valcare Medical Ltd.
Not applicable
15
Arizona, California, Georgia, Indiana, New York, Oregon, Tennessee, Texas
2025-09-11
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
220
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-09-10
Recruiting
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
NCT06784466Atrial Fibrillation (AF), Persistant Atrial Fibrillation, Paroxysmal AF
Arga Medtech SA
Not applicable
360
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas
2025-09-10
Recruiting
Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
NCT07059962Kidney Disease, Peritoneal Dialysis (PD), End Stage Kidney Disease (ESRD)
Bodyport Inc.
Observational
125
California, Georgia, Illinois
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3
720
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-09-08
Active, closed
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
NCT07128615Influenza A
AstraZeneca
Phase 1/2
405
California, Florida, Georgia, Illinois, Kansas, Missouri, Nebraska, Nevada
2025-09-04
Recruiting
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT07061288Schizophrenia
Bristol-Myers Squibb
Phase 1
131
California, Florida, Georgia, Illinois, New Jersey, Texas
2025-09-03
By invitation
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-09-02
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-09-02
Recruiting
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
Neurocrine Biosciences
Phase 4
100
Arkansas, California, Florida, Georgia, Illinois, Nebraska, Ohio, Texas
2025-08-29
Recruiting
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
NCT07191483Cognitive Impairment Associated With Schizophrenia (CIAS)
Kynexis B.V.
Phase 2
150
Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri, New Jersey
2025-08-27
Active, closed
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
NCT07122193Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
Merz North America, Inc.
Phase 3
300
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-08-27
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
Relay Therapeutics, Inc.
Phase 3
540
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2025-08-26
Recruiting
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT07145229Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
Atom Therapeutics Co., Ltd
Phase 2
380
Arizona, California, Georgia, Illinois, Iowa, Louisiana, Maryland, Mississippi
2025-08-26
Recruiting
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843Primary Membranous Nephropathy
Climb Bio, Inc.
Phase 2
45
Colorado, Florida, Georgia, Indiana, Massachusetts, New York, Texas
2025-08-25
Recruiting
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
NCT07136012Cardiovascular Disease
Amgen
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-08-22
Recruiting
Study of BHV-1300 in Graves' Disease
NCT06980649Graves Disease
Biohaven Therapeutics Ltd.
Phase 1
15
California, Florida, Georgia, North Carolina, Ohio, Tennessee, Texas
2025-08-21
Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
NCT06959524Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Boston Scientific Corporation
Not applicable
1,616
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-08-21
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700Episodic Migraine
Merz Therapeutics GmbH
Phase 3
990
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Kansas
2025-08-21
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC
Phase 2/3
153
Delaware, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Ohio, West Virginia
2025-08-21
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713Chronic Migraine
Merz Therapeutics GmbH
Phase 3
780
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Kansas
2025-08-21
Recruiting
Real Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS)
NCT07135284Bronchiectasis Adult
Synchrony-Medical, Ltd
Observational
200
Alabama, Georgia, South Carolina
2025-08-20
Active, closed
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 2
240
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Montana
2025-08-19
Active, closed
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Tisento Therapeutics
Phase 2
44
California, Colorado, Georgia, Massachusetts, New York, Ohio, Pennsylvania, Texas
2025-08-18
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Amgen
Phase 3
350
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-08-18
Recruiting
The Sentio System: Post-market Evaluation of Safety and Performance in Adolescents
NCT06844071Hearing Loss
Oticon Medical
Observational
25
Georgia
2025-08-15
Recruiting
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Nevada, New Jersey, Ohio
2025-08-15
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
150
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-08-14
Recruiting
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
NCT07209475Diabetic Foot Ulcer (DFU), Amnio-Maxx
Royal Biologics
Phase 4
248
California, Florida, Georgia, Nebraska, New York, Oklahoma, Texas
2025-08-14
Recruiting
Abbott Cephea Mitral Valve Disease Registry
NCT07069673Mitral Regurgitation, Mitral Stenosis, Mitral Valve Disease, Mitral Valve (MV) Regurgitation
Abbott Medical Devices
Observational
1,000
Alabama, Arizona, California, Georgia, Illinois, Indiana, Kansas, Minnesota
2025-08-13
Recruiting
Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).
NCT07042516Vasomotor Symptoms
Tioga Pharmaceuticals
Phase 2
120
Georgia
2025-08-13
Recruiting
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT07096674Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Centessa Pharmaceuticals (UK) Limited
Phase 2
90
Alabama, California, Florida, Georgia, Michigan, Nevada, North Carolina, Ohio
2025-08-12
Active, closed
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
NCT07055451HIV-1-infection
Gilead Sciences
Phase 1
16
California, Georgia, Tennessee
2025-08-12
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
BioNTech SE
Phase 1/2
1,438
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New York
2025-08-12
Active, closed
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199Diabetes Mellitus, Type 1
Novo Nordisk A/S
Phase 3
877
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-08-11
Recruiting
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT07105098Schizophrenia
Neurocrine Biosciences
Phase 3
284
California, Georgia, Ohio
2025-08-11
Recruiting
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
NCT07172516Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
Xenon Pharmaceuticals Inc.
Phase 3
400
Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri, Nevada
2025-08-08
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
AstraZeneca
Phase 2
278
California, Georgia, Maryland, Texas, Virginia
2025-08-07
Recruiting
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849Sickle Cell Disease Vaso-occlusive Crisis
CSL Behring
Phase 2
70
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, Missouri
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
California, Florida, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania
2025-08-06
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
AstraZeneca
Phase 3
700
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-08-06
By invitation
Acolyte CTO-PCI Study: Imaging and Catheter System to Treat Patients With Coronary Chronic Total Occlusion, Who Have Persistent Symptoms Following Medical Therapy and Are Undergoing Percutaneous Coronary Interventional Procedures
NCT06795763Coronary Chronic Total Occlusions, Ischemic Heart Disease, Ischemic Heart Disease (IHD), Ischemic Heart Disease Chronic
Elumn8 Medical
Not applicable
115
Georgia, Minnesota, New York, Texas
2025-08-06
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho, Kentucky
2025-08-06
Recruiting
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
NCT07133308Alopecia Areata
Sun Pharmaceutical Industries, Inc.
Phase 3
355
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-08-05
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
Pfizer
Phase 3
400
Arizona, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2025-08-05
Recruiting
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
NCT07089888Tophaceous Gout
Crystalys Therapeutics
Phase 3
250
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-08-04
Recruiting
A Study of Dotinurad Versus Allopurinol in Participants With Gout
NCT07089875Gout
Crystalys Therapeutics
Phase 3
500
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-08-01
Recruiting
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
NCT07073547Multiple Myeloma
AstraZeneca
Phase 1
40
Arizona, California, Colorado, Florida, Georgia, Iowa, Minnesota, Missouri
2025-07-31
Active, closed
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
NCT07044297Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC
Phase 3
4,390
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Louisiana, Mississippi
2025-07-31
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors
Amgen
Phase 1
434
California, Georgia, Massachusetts, Missouri, North Carolina, Pennsylvania, Tennessee, Texas
2025-07-31
Recruiting
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
NCT07002034Adjustment Disorder
Reunion Neuroscience Inc
Phase 2
100
Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois
2025-07-30
Recruiting
Study of BHV-1400 in IgA Nephropathy
NCT07054684IgA Nephropathy
Biohaven Therapeutics Ltd.
Phase 1
20
Connecticut, Florida, Georgia, Illinois, Indiana, Michigan, Missouri, South Dakota
2025-07-30
Recruiting
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
NCT06328608Fabry Disease
Chiesi Farmaceutici S.p.A.
Phase 2/3
22
Arizona, Georgia, Iowa, Ohio, Utah, Virginia
2025-07-29
Recruiting
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
NCT06850805Chronic Rhinosinusitis Without Nasal Polyps
Optinose US Inc.
Phase 3
84
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kentucky, Maryland
2025-07-28
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502Follicular Lymphoma
Celgene
Phase 3
400
Alabama, Alaska, Arkansas, California, Florida, Georgia, Illinois, Iowa
2025-07-28
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519Ulcerative Colitis
AbbVie
Phase 3
120
Arizona, California, Florida, Georgia, Illinois, New Jersey, Ohio, Pennsylvania
2025-07-28
Recruiting
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
NCT07080905Hemophilia B
CSL Behring
Phase 3
20
California, Florida, Georgia, Michigan, Tennessee
2025-07-28
Not yet open
A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis
NCT06989567Sickle Cell Disease
Asklepion Pharmaceuticals, LLC
Phase 3
120
District of Columbia, Florida, Georgia, Maryland, Michigan, North Carolina
2025-07-25
Recruiting
ELEVATE High-Risk PCI Pivotal Study
NCT07001332High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Magenta Medical Ltd.
Not applicable
290
Arizona, California, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-07-25
Rows per page Showing 501–600 of 2346
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-usa/state/georgia?page=6

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,115 studies in total at the last sync on 24 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,346 of those studies with a site in Georgia.

How many clinical trials are recruiting in Georgia?

1,211 of the 2,346 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:16 UTC sync. A further 40 have not yet opened recruitment, 1,035 are active but closed to new participants, and 60 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.